Recursion Pharmaceuticals (RXRX) Net Margin (2020 - 2026)
Recursion Pharmaceuticals (RXRX) reported Net Margin of 1815.57% for Q1 2026, down 44232.0% on a YoY basis from N/an in Q1 2025, and down 496.75% quarter-over-quarter from 304.24% in Q4 2025.
Recursion Pharmaceuticals (RXRX) Net Margin (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals has reported Net Margin for 7 years, with the latest figure at 1815.57% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin fell 44232.0% year-over-year to 1815.57%; the trailing twelve-month figure through Mar 2026 stood at 842.93% (up 11839.0% YoY), and the FY2025 full-year result was 863.35%, down 7533.0% from the prior year.
- Net Margin for Q1 2026 stood at 1815.57%, down from 304.24% in the prior quarter.
- The five-year high for Net Margin was 304.24% in Q4 2025, with the low at 3935.46% in Q4 2024.
- Historically, Net Margin has averaged 1115.88% across 5 years, with a median of 853.88% in 2023.
- Annual changes were most pronounced in 2024 — Net Margin slumped 308158 bps — and 2025, when it jumped 363122 bps.
- Recursion Pharmaceuticals' Net Margin stood at 445.91% in 2022, then tumbled by 91 bps to 853.88% in 2023, then tumbled by 361 bps to 3935.46% in 2024, then jumped by 92 bps to 304.24% in 2025, then slumped by 497 bps to 1815.57% in 2026.
- The last three Net Margin figures came in at 1815.57% (Q1 2026), 304.24% (Q4 2025), and 3135.32% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.71 Bn | 1.05 Bn | -6.02 Mn | -1,815.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,815.57% |
| Dec 31, 2025 | -304.24% |
| Sep 30, 2025 | -3,135.32% |
| Jun 30, 2025 | -894.23% |
| Mar 31, 2025 | -1,373.26% |
| Dec 31, 2024 | -3,935.46% |
| Sep 30, 2024 | -367.46% |
| Jun 30, 2024 | -676.56% |
| Mar 31, 2024 | -662.41% |
| Dec 31, 2023 | -853.88% |
| Sep 30, 2023 | -883.10% |
| Jun 30, 2023 | -696.43% |
| Mar 31, 2023 | -538.38% |
| Dec 31, 2022 | -445.91% |
| Sep 30, 2022 | -475.48% |
| Jun 30, 2022 | -862.54% |
| Mar 31, 2022 | -1,049.71% |
| Dec 31, 2021 | -2,564.55% |
| Sep 30, 2021 | -1,831.18% |
| Jun 30, 2021 | -1,605.69% |